When Vomiting on Zepbound (tirzepatide) Becomes a Reason to Stop

At a glance

• Vomiting rates / 8% at 5 mg, 11% at 10 mg, 13% at 15 mg vs 2% placebo in pooled weight trials [1]
• Severe GI reactions / 1.7% at 5 mg, 2.5% at 10 mg, 3.1% at 15 mg vs 1% placebo [1]
• GI-related discontinuation / 1.9%, 3.3%, 4.3% vs 0.5% placebo [1]
• Suspected pancreatitis / the label says to discontinue Zepbound and start appropriate management [1]
• Volume depletion / monitor renal function, especially during initiation and escalation [1]
• Severe gastroparesis / Zepbound not recommended [1]

Does the Zepbound label give a vomiting threshold for stopping?

No. The warnings and adverse reactions sections list vomiting as a common GI adverse reaction; they do not set a number of episodes at which to stop [1]. The label says most nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time [1].

How common is vomiting on Zepbound?

In the pooled placebo-controlled weight-reduction trials, vomiting was reported by 8% of patients on 5 mg, 11% on 10 mg, and 13% on 15 mg, versus 2% on placebo [1]. The pool included 958 placebo patients, 630 on 5 mg, 948 on 10 mg, and 941 on 15 mg, treated for up to 72 weeks [1]. Any GI adverse reaction occurred in 56% of patients on every Zepbound dose versus 30% on placebo [1]. Discontinuation due to a GI adverse reaction was 1.9% on 5 mg, 3.3% on 10 mg, and 4.3% on 15 mg versus 0.5% on placebo [1]. Severe gastrointestinal adverse reactions were reported in 1.7%, 2.5%, and 3.1% versus 1% on placebo [1].

What does the label say if a dose is not tolerated?

The recommended schedule starts at 2.5 mg once weekly for 4 weeks, then 5 mg, with increases in 2.5 mg steps after at least 4 weeks on the current dose [1]. The 2.5 mg dose is for treatment initiation and is not approved as a maintenance dosage [1]. The label describes the escalation schedule as a way to reduce the risk of gastrointestinal adverse reactions [1]. For weight reduction, maintenance doses are 5, 10, or 15 mg once weekly, with a maximum of 15 mg once weekly [1]. If patients do not tolerate a maintenance dosage, the label says to consider a lower maintenance dosage [1].

When does the label say to discontinue?

Among the label warnings that can involve vomiting, the explicit stop instruction is for suspected pancreatitis. The label says to observe patients for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and that if pancreatitis is suspected, Zepbound should be discontinued and appropriate management started [1]. In the pooled weight-reduction trials, adjudication-confirmed acute pancreatitis occurred in 0.2% of Zepbound-treated patients and 0.2% of placebo-treated patients; in the pooled sleep apnea studies the rate was 0.84 per 100 patient-years on Zepbound and 0 on placebo [1]. The label also says to discontinue Zepbound if a serious hypersensitivity reaction is suspected [1]. The label also warns about acute kidney injury due to volume depletion, with postmarketing reports in patients who had GI adverse reactions leading to dehydration such as nausea, vomiting, or diarrhea; it says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and escalation [1]. Zepbound is not recommended in patients with severe gastroparesis [1].

Frequently asked questions

›What symptoms with vomiting suggest pancreatitis?

The label says to watch for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the Zepbound label calls for discontinuing treatment and starting appropriate management [1].

›Can vomiting on Zepbound cause kidney injury?

The label warns of acute kidney injury due to volume depletion. Most reported events were in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and escalation [1].

›How often did gastrointestinal side effects lead to stopping in trials?

In the pooled weight-reduction trials, GI adverse reactions led to discontinuation in 1.9% on 5 mg, 3.3% on 10 mg, and 4.3% on 15 mg, versus 0.5% on placebo [1]. Discontinuation for any adverse reaction was 4.8%, 6.3%, and 6.7% versus 3.4% [1].

›What happened to weight in the trial that stopped tirzepatide?

In SURMOUNT-4, 783 adults received 36 weeks of open-label tirzepatide (10 or 15 mg), and the 670 who were then randomized had a mean weight reduction of 20.9%. From week 36 to week 88, weight changed by -5.5% with continued tirzepatide and +14.0% after switching to placebo [2].

References

1. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
2. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial